Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2411 vs EU-Prolia in postmenopausal women with osteoporosis
jRCT2080224911Phase 3Completed
- Sponsor
- Sandoz
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by Sandoz. Primary endpoints: Pharmacokinetics similarity, Pharmacodynamics similarity and 1 more. Started Oct 2019; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT2080224911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224911.